AOA 2023: Investigating 3-layer amniotic membrane graft as an emerging treatment for ocular surface disease

Video

Harmin Chima, OD, met with Optometry Times to discuss treatment options for ocular surface disease with Biovance's 3-layer amniotic membrane graft.

Video Transcript

Editor's note: this transcript has been lightly edited for clarity.

Harmin Chima, OD:

Hello, everybody. My name is Harmin Chima, and I practice in the Cleveland, Ohio area. Our poster focused on Biovance's 3L membrane, which is a triple-layer amniotic membrane for ocular surface disease and for eye injuries.

Over 7 million people suffer from dry eye disease, and a lot of these patients are not finding relief from traditional therapies like artificial tears, punctal occlusion, and immunomodulators. So, we really wanted to focus on a more robust form of treatment, and we wanted to explore how the Biovances's triple-layer membrane would work with our patients. We treated 18 eyes in the clinical study, and we found a vast improvement across multiple metrics. The most important metrics were the SPEED score, which is a questionnaire to objectify your dry eye disease and best-corrected visual acuity. In both categories, we saw significant improvement across the board.

I think, clinically, this product has tremendous potential because we're seeing so many patients that are not getting the relief that they need for dry eye disease. So, we have another tool in our pocket for our patients that have more significant ocular surface disease in addition to ocular injuries, like corneal abrasions and recurrent corneal erosions.

So in conclusion, Biovance triple-layer membrane is a novel, easy to handle, decellularized membrane that we can use on our patients with significant ocular surface disease and corneal injuries.

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.